Literature DB >> 16198662

Imatinib induces hypothyroidism in patients receiving levothyroxine.

Jan Willem B de Groot1, Bernard A Zonnenberg, John T M Plukker, Winette T A van Der Graaf, Thera P Links.   

Abstract

Interactions of imatinib with other drugs have been scarcely reported. We report a previously unknown effect of imatinib on levothyroxine therapy. Eleven patients (1 with gastrointestinal stromal tumor and 10 with medullary thyroid carcinoma) received imatinib. Eight had undergone thyroidectomy and used levothyroxine, and 3 had the thyroid in situ. Thyroid function was measured before, during, and within 2 weeks after any change in either imatinib or levothyroxine dosage. We observed symptoms of hypothyroidism in all patients who had undergone thyroidectomy, whereas patients with the thyroid in situ remained clinically and biochemically euthyroid. On average, thyrotropin (INN, thyrotrophin) levels increased to 384% +/- 228% of the upper limit in patients after thyroidectomy, whereas free thyroxine (fT4) and free tri-iodothyronine (fT3) values remained within the reference range (59% +/- 17% of the upper limit for fT4 and 63% +/- 4% of the upper limit for fT3). Clinicians should be aware that hypothyroid subjects receiving imatinib have a high likelihood for increased levothyroxine replacement and should be closely monitored for elevations in thyrotropin indicating worsening hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198662     DOI: 10.1016/j.clpt.2005.06.010

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  31 in total

Review 1.  Anticancer Drug-induced Thyroid Dysfunction.

Authors:  Saptarshi Bhattacharya; Alpesh Goyal; Parjeet Kaur; Randeep Singh; Sanjay Kalra
Journal:  Eur Endocrinol       Date:  2020-02-04

Review 2.  Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

Authors:  Rebecca L Brown
Journal:  Target Oncol       Date:  2011-11-19       Impact factor: 4.493

Review 3.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

4.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 5.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

Review 6.  Endocrine side effects of broad-acting kinase inhibitors.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

Review 7.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

Review 8.  Drugs that suppress TSH or cause central hypothyroidism.

Authors:  Bryan R Haugen
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

9.  Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.

Authors:  Egidio Del Fabbro; Rony Dev; Maria E Cabanillas; Naifa L Busaidy; EdenMae C Rodriguez; Eduardo Bruera
Journal:  J Chemother       Date:  2012-08       Impact factor: 1.714

10.  Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.

Authors:  Sahzene Yavuz; Andrea B Apolo; Shivaani Kummar; Jaydira del Rivero; Ravi A Madan; Thomas Shawker; James Reynolds; Francesco S Celi
Journal:  Thyroid       Date:  2014-06-05       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.